


# Antabio Implement Web-based Informatics Solution to Facilitate Global Collaborations

---





**Antabio is a private biopharmaceutical company developing a broad pipeline of novel antibacterial treatments focused on drug-resistant life threatening infections.**

All Antabio programs address WHO critical priority pathogens and are eligible for streamlined development. Founded in 2009 by Marc Lemonnier, Antabio has built a best in class, international team with highly successful track records including former executives from Novexel, Galapagos, Merck, GSK and Astra Zeneca. The company is headquartered near Toulouse, France and has UK and US subsidiaries.

*“Antabio has built an international team of experts to understand and resolve the most urgent unmet medical needs of the antibacterial space. We are dedicated to developing a pipeline of novel antibacterial treatments to address infections caused by WHO’s priority pathogens and fill important gaps in the antibiotic armamentarium.”*

Martin has over 25 years’ experience in academia, pharmaceutical R&D (GSK) and biotechnology (MerLion, Antabio). At GSK he worked in anti-tubercular target development before managing an automated high-throughput screening group and leading several antibacterial and oncology lead discovery projects. At MerLion he was Head of Research leading a multi-disciplinary team discovering and developing novel natural product derived compounds. Martin joined Antabio in 2012.



**Dr Martin Everett**  
CSO  
Antabio

Jérôme is a microbiologist with experience in academia and pharmaceutical R&D at Sanofi. He joined Antabio 10 years ago as the first employee of the company and is currently senior R&D Biologist, Laboratory Manager and Safety Officer. He is now administrator of the Dotmatics Platform and manages all the biochemical and enzymatic activities for Wellcome Trust and CarbX-funded projects. Jérôme was awarded his PhD by the Université Paul Sabatier, Toulouse.



**Dr Jérôme Castandet**  
Senior R&D Biologist  
Antabio

## The Challenge: Disparate Research Data with Increased Number and Complexity of Lead Programs

---

Like many biotechnology start-up companies, Antabio began with a single program in hit to lead phase. With just two employees initially, the scientists used a simple chemistry enabled database to which they could associate structures and data. All analysis was done manually in excel and the results then stored in this database.

Once the company started to expand, scientists were making many more molecules and introducing different assays.

### They quickly became frustrated with:

- Time taken to analyze data
- Risks inherent in manual data manipulations
- Inability to capture or link the data to the raw data and parameters of the assays
- Lack of ability to follow any variations in assay protocols
- Lack of project oversight

*“Really the previous system was designed only to store results.”*

*Jérôme Castandet*

*“I’d used much more complex data solutions at GSK and MerLion so it was clear that we needed something that was going to be a proper platform for us to develop and expand into, allowing us to archive, distribute and search our data in a format that would grow with us.”*

*Martin Everett*


## The Approach: A Global Collaboration Environment

---

Antabio has scientists across three countries who need access to all project data and also works with CRO partners. In addition to its main site near Toulouse, the US subsidiary is involved in pre-clinical and clinical development and the UK subsidiary is home to both the CSO and the Head of Chemistry. At the time of investigating informatics solutions, Antabio’s main chemistry CRO partner for lead optimization molecules recommended the Dotmatics Platform, which it had already adopted.

*“Our chemistry CRO partner had good things to say about it so we thought we’d try the Dotmatics Informatics Platform and it meant it was much easier for us to share data, both directly and on the cloud.”*

*Martin Everett*




## The Solution: A Web-based Integrated Solution for Data Capture and Analytics

**Antabio decided on a web-based informatics system to facilitate collaborating with colleagues across the globe in addition to CRO partners. Access to all scientific experiments, data and knowledge was a priority for their project progression decisions.**

After a full review of the market, Antabio chose the Dotmatics solution in 2014 and, with the help of the implementation team, configured the system to cover the following key areas:

- Assay data
- IC50 and KI results directly from enzyme assays
- MICs, bacterial susceptibility, plate set-up for which is non-standard and complex
- Project overview: Combining data in a Browser project view, relating structural data, registration data, assay and other experimental results
- Analytics with Browser and Vortex



*“We enjoyed working with the Dotmatics implementation team. They are responsive and really very good!”*

*Jérôme Castandet*



## The Outcome: Enhanced Project Oversight & Efficient Analyses

**Scientists at Antabio are now able to see all data necessary for making project progression decisions and senior management have up to date information for accurate planning.**

Researchers no longer have the burden of moving data about between systems with the inherent risks of propagating errors. Scientists can spend more of their time analyzing results and making judgements on the quality and acceptability of data rather than on data manipulation. In addition, both IC50 and MIC analyses can be done within the one system.

Antabio scientists could see the benefits of an integrated solution and worked closely with Dotmatics to define their research workflows which includes collaborations with external partner organizations.

Antabio currently has three programmes in preclinical development and the future involves more detailed work on individual molecules.

*“Now the data is all brought together in one place in Browser we can directly analyze the raw data on the system and directly link with the summary of all compounds in the same interface. For me this is the main advantage of the platform”*

*Jérôme Castandet*



**Martin Everett**

Previously, we analyzed all the data in excel files which was extremely hands on, took a long time and had a lot of risk of error and lack of ability to track what you're doing.

Now that the solution is in the same platform there's an efficiency in terms of time but more importantly for us an improvement in term of quality, reproducibility and consistency of the data management.




**Jérôme Castandet**

With the previous process it easily took an hour to analyze a single simple experiment, now it takes less than ten minutes.



**Martin Everett**

Of course, there's an investment in setting it up the protocols, getting those right and training people how to use it but once that's set up it's very quick. We simply couldn't carry out the number of experimental analyses we currently do, if we still had the previous system.



#### Contact

Info: [info@dotmatics.com](mailto:info@dotmatics.com)  
Sales: [sales@dotmatics.com](mailto:sales@dotmatics.com)  
Support: [support@dotmatics.com](mailto:support@dotmatics.com)  
Careers: [careers@dotmatics.com](mailto:careers@dotmatics.com)

**Dotmatics**